What is Vault Pharma?
Vault Pharma operates at the intersection of immunology and precision medicine, leveraging a proprietary platform based on naturally occurring human vault particles. By utilizing these biological structures to deliver targeted therapeutic agents, the company addresses complex disease states including oncology, infectious diseases, and auto-immune disorders. The firm distinguishes itself through a collaborative model, engaging with pharmaceutical, academic, and government partners to refine its drug discovery processes. This strategic positioning allows Vault Pharma to maintain a robust research pipeline, notably addressing global health challenges such as COVID-19 while pushing the boundaries of targeted immune system modulation.
How much funding has Vault Pharma raised?
Vault Pharma has raised a total of $56K across 1 funding round:
Debt
$56K
Debt (2021): $56K with participation from PPP
Key Investors in Vault Pharma
PPP
Public-Private Partnership
What's next for Vault Pharma?
Following this latest financing round, Vault Pharma is expected to prioritize the advancement of its lead candidates into late-stage clinical trials. The capital will likely be deployed to enhance manufacturing capabilities and expand the internal research team, ensuring the company can sustain its momentum in the competitive biotech landscape. As the firm transitions from a research-heavy entity to a clinical-stage powerhouse, stakeholders will be monitoring the progression of its vault-particle delivery system. Future growth will likely hinge on the successful validation of its therapeutic candidates and the potential for strategic licensing agreements that could further solidify its market dominance in the immunology sector.
See full Vault Pharma company page
